12

September

2016

MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium difficile-associated Diarrhoea (CDAD) for MGB-BP-3

Glasgow, Scotland, 12th September 2016 – MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of...

Read More

14

June

2016

MGB Biopharma to Present Poster at Upcoming ASM Microbe Meeting in Boston on 20 June 2016

Glasgow, Scotland, 14th June 2016 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

19

May

2016

MGB Biopharma Welcomes Jim O’Neill’s Final Recommendations for the World to Defeat Superbugs

Glasgow, Scotland, 19th May 2016 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, welcomes the final instalment of Lord...

Read More

9

May

2016

MGB Biopharma’s Pre-IND Meeting with FDA Provides Clear Guidelines on Further Development of Oral MGB-BP-3, a Truly Novel Antibiotic Targeting Clostridium difficile Infections

Glasgow, Scotland, 9 May 2016 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

16

February

2016

MGB Biopharma and University of Strathclyde Sign New Agreement to Develop Novel MGB Anti-Infectives to Tackle a Key Mechanism of AMR

Glasgow, Scotland, 15 February 2016 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

9

December

2015

MGB Biopharma successfully completes Phase I clinical trial with Oral MGB-BP-3 – a truly novel antibiotic targeting Clostridium difficile infections

Glasgow, Scotland, 8th December 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

17

November

2015

MGB Biopharma Successfully Completes Feasibility Study with Topical Formulation of its Lead Antibacterial MGB-BP-3

Glasgow, Scotland, 17 November 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has successfully...

Read More

29

October

2015

MGB Biopharma to attend BIO-Europe 2015

Glasgow, Scotland, 29 October 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

10

September

2015

MGB Biopharma Wins Scottish Business Award

Glasgow, Scotland, 10th September 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

21

July

2015

MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections

Glasgow, Scotland, 21st July 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem...

Read More